The AGO Study Group is a non-profit organisation with the aim to enhance the therapy of pelvic tumours in women. It developed from the AGO Ovarian Cancer Study Group, which was founded in 1993.
Ovar
Primary diseas
AGO-OVAR 1/2
Phase I/II study of the combination of carboplatin and paclitaxel as first-line therapy patients with advanced epithelial ovarian cancer
A. du Bois, H.-J. Lück, T. Bauknecht, V. Möbus, H. Bochtler, K. Diergarten & H.-G. Meerpohl
Annals of Oncology 8: 335-361 (1997)
Phase I/II study of the combination of carboplatin and paclitaxel as first-line therapy patients with advanced epithelial ovarian cancer
A. du Bois, H.-J. Lück, T. Bauknecht, V. Möbus, H. Bochtler, K. Diergarten & H.-G. Meerpohl
Annals of Oncology 8: 335-361 (1997)
AGO-OVAR 2.9
Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel an carboplatin for patients with platinum-sensitive ovarian cancer in late relapse
Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey P A, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, and du Bois A
J Clin Oncol 28:3323-3329, 2010
AGO-OVAR 3
A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer
du Bois A, Lück H.-J, Meier W, Adams H-P, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J, for the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group
J Natl Cancer Inst 2003; 95:1320-30
A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer
du Bois A, Lück H.-J, Meier W, Adams H-P, Möbus V, Costa S, Bauknecht T, Richter B, Warm M, Schröder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J, for the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group
J Natl Cancer Inst 2003; 95:1320-30
AGO-OVAR 4
First-line chemotherapy with epirubicin, paclitaxel, and Carboplatin (ET-Carbo) for advanced ovarian carcinoma. A phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group
A du Bois, HJ Lück, T Bauknecht, W Meier, B Richter, J Pfisterer, J Quaas, W Kuhn
J Clin Oncol 17: 46-51, 1999
First-line chemotherapy with epirubicin, paclitaxel, and Carboplatin (ET-Carbo) for advanced ovarian carcinoma. A phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group
A du Bois, HJ Lück, T Bauknecht, W Meier, B Richter, J Pfisterer, J Quaas, W Kuhn
J Clin Oncol 17: 46-51, 1999
AGO-OVAR 5
Addition of epirubicin as third drug to carboplatin-paclitaxel in firstline treatment of advanced ovarian cancer. ......
du Bois A, Weber B, Rochon J, Meier W, Goupil A, Olbricht S, Barats Jean-Claude, Kuhn W, Orfeuvre H, Wagner U, Richter B, Lueck HJ, Pfisterer J, Costa S, Schroeder W, Kimmig R, Pujade-Lauraine E for AGO-OVAR and GINECO
J Clin Oncol 24: 1127-1135
Addition of epirubicin as third drug to carboplatin-paclitaxel in firstline treatment of advanced ovarian cancer. ......
du Bois A, Weber B, Rochon J, Meier W, Goupil A, Olbricht S, Barats Jean-Claude, Kuhn W, Orfeuvre H, Wagner U, Richter B, Lueck HJ, Pfisterer J, Costa S, Schroeder W, Kimmig R, Pujade-Lauraine E for AGO-OVAR and GINECO
J Clin Oncol 24: 1127-1135
AGO-OVAR 6
Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group
Pfisterer J, du Bois A, Wagner U, Quaas J, Blohmer JU, Wallwiener D and Hilpert F
Gynecologic Oncology 92 (2004) 949-956
Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group
Pfisterer J, du Bois A, Wagner U, Quaas J, Blohmer JU, Wallwiener D and Hilpert F
Gynecologic Oncology 92 (2004) 949-956
AGO-OVAR 7
Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO
Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stähle A, Jackisch C, Hardy-Bessard AC, Möbus V, Quaas J, Richter B, Schröder W, Geay JF, Lück HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E for the AGO-OVAR and GINECO
J Natl Cancer Inst 2006; 98:1036-1045
Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO
Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stähle A, Jackisch C, Hardy-Bessard AC, Möbus V, Quaas J, Richter B, Schröder W, Geay JF, Lück HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E for the AGO-OVAR and GINECO
J Natl Cancer Inst 2006; 98:1036-1045
AGO-OVAR 8
A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8)
du Bois A, Belau A, Wagner U, Pfisterer J , Schmalfeldt B, Richter B, Stähle A, Jackisch C, Lueck H-J, Schroeder W, Olbricht S, Elser G and for the Arbeitsgemeinschaft Gyneaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)
Gynecol Oncol 96 (2005) 444-451
A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8)
du Bois A, Belau A, Wagner U, Pfisterer J , Schmalfeldt B, Richter B, Stähle A, Jackisch C, Lueck H-J, Schroeder W, Olbricht S, Elser G and for the Arbeitsgemeinschaft Gyneaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)
Gynecol Oncol 96 (2005) 444-451
Recurrent diseas
AGO-OVAR 2.1
Chemotherapy versus Hormonal Treatment in Platinum- and Paclitaxel-Refractory Ovarian Cancer: A Randomized Trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer
A du Bois, W Meier, HJ Lück, G Emons, V Möbus, W Schröder, S Costa, T Bauknecht, S Olbricht, C Jackisch, B Richter, U Wagner
Annals of Oncology 13:251-257,2002
Chemotherapy versus Hormonal Treatment in Platinum- and Paclitaxel-Refractory Ovarian Cancer: A Randomized Trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer
A du Bois, W Meier, HJ Lück, G Emons, V Möbus, W Schröder, S Costa, T Bauknecht, S Olbricht, C Jackisch, B Richter, U Wagner
Annals of Oncology 13:251-257,2002
AGO-OVAR 2.2
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR 2.2 trial
The ICON and AGO Collaborators (writing committee)
Lancet 361: 2099-2106 (2003)
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR 2.2 trial
The ICON and AGO Collaborators (writing committee)
Lancet 361: 2099-2106 (2003)
AGO-OVAR 2.4
2nd-line chemotherapy with carboplatin and gemcitabine in patients with platinum sensitive recurrent ovarian cancer. A phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group
A du Bois, HJ Lück, J Pfisterer, W Schroeder, JU Blohmer, R Kimmig, V Moebus, J Quaas
Annals of Oncology 12: 1115-1120, 2001
2nd-line chemotherapy with carboplatin and gemcitabine in patients with platinum sensitive recurrent ovarian cancer. A phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group
A du Bois, HJ Lück, J Pfisterer, W Schroeder, JU Blohmer, R Kimmig, V Moebus, J Quaas
Annals of Oncology 12: 1115-1120, 2001
AGO-OVAR 2.5
Gemcitabine plus carboplatin versus carboplatin in patients with platinum-sensitive-recurrent ovarian cancer
Pfisterer J, Plante M, Vergote I, Zimmerman A, du Bois A, Hirte H, Lacave A J, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück H-J, Rochon J, Zimmermann A H, Eisenhauer E for the AGO OVAR, NCIC CTG and EORTC GCGPfisterer J, Plante M, Vergote I, Zimmerman A, du Bois A, Hirte H, Lacave A J, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück H-J, Rochon J, Zimmermann A H, Eisenhauer E for the AGO OVAR, NCIC CTG and EORTC GCG
J Clin Oncol 24:4699-4707, 2006
Gemcitabine plus carboplatin versus carboplatin in patients with platinum-sensitive-recurrent ovarian cancer
Pfisterer J, Plante M, Vergote I, Zimmerman A, du Bois A, Hirte H, Lacave A J, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück H-J, Rochon J, Zimmermann A H, Eisenhauer E for the AGO OVAR, NCIC CTG and EORTC GCGPfisterer J, Plante M, Vergote I, Zimmerman A, du Bois A, Hirte H, Lacave A J, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück H-J, Rochon J, Zimmermann A H, Eisenhauer E for the AGO OVAR, NCIC CTG and EORTC GCG
J Clin Oncol 24:4699-4707, 2006
AGO-OVAR 2.6
Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy – A phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)
Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy – A phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)
Wagner U, du Bois A, Pfisterer J, Huober J, Loibl S, Lück HJ, Sehouli J, Gropp M, Stähle A, Schmalfeldt, B, Meier W, Jackisch C
Gynecol Oncol 2007; 105:132-137
Gynecol Oncol 2007; 105:132-137
AGO-OVAR 2.8
The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer - A phase I trial of the AGO-OVAR
Pfisterer J, du Bois A, Sehouli J, Loibl S, Reinartz S, Reuß A, Canzler U, Belau A, Jackisch C, Kimmig R, Wollschlaeger K, Heilmann V, Hilpert , On behalf of the AGO-OVAR
Ann Oncol 17: 1568-1577, 2006
The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer - A phase I trial of the AGO-OVAR
Pfisterer J, du Bois A, Sehouli J, Loibl S, Reinartz S, Reuß A, Canzler U, Belau A, Jackisch C, Kimmig R, Wollschlaeger K, Heilmann V, Hilpert , On behalf of the AGO-OVAR
Ann Oncol 17: 1568-1577, 2006
Uterus
AGO GYN 2
Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)
A. du Bois, A. Burges, W. Meier, J. Pfisterer, B. Schmalfeldt, B. Richter, C. Jackisch, A. Staehle, R. Kimmig & G. Elser on behalf of AGO-OVAR Germany
Annals of Oncology 17: 93-96, 2006
Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)
A. du Bois, A. Burges, W. Meier, J. Pfisterer, B. Schmalfeldt, B. Richter, C. Jackisch, A. Staehle, R. Kimmig & G. Elser on behalf of AGO-OVAR Germany
Annals of Oncology 17: 93-96, 2006
AGO GYN 3
Combination Therapy with Pegylated Liposomal Doxorubicin and Carboplatin in Gynecologic Malignancies: A Prospective Phase-II Study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut)
du Bois A, Pfisterer J, Burchardi N, Loibl S, Huober J, Wimberger P, Burges A, Staehle A, Jackisch C, Koelbl H
Gynecol Oncol 2007; 107: 518-525
Gynecol Oncol 2007; 107: 518-525
AGO GYN 4
A Phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
du Bois A, Huober J, Stopfer P, Pfisterer J, Wimberger P, Loibl S Reichardt V, Harter P
Annals of Oncol 2010 21:370-375
A Phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
du Bois A, Huober J, Stopfer P, Pfisterer J, Wimberger P, Loibl S Reichardt V, Harter P
Annals of Oncol 2010 21:370-375
Clinical trials in surgical settings
AGO-OVAR OP.1/DESKTOP I
Surgery in recurrent ovarian cancer - The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial
Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Schröder W, Muenstedt K, Schmalfeldt B, Emons G, Pfisterer J, Wollschlaeger K, Meerpohl HG, Breitbach GP, Tanner B, Sehouli J. Heilmann V for the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee (AGO OC) and the AGO Ovarian Cancer Study Group (AGO-OVAR)
Ann Surg Oncol 2006 online first 10-2006
Surgery in recurrent ovarian cancer - The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial
Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Schröder W, Muenstedt K, Schmalfeldt B, Emons G, Pfisterer J, Wollschlaeger K, Meerpohl HG, Breitbach GP, Tanner B, Sehouli J. Heilmann V for the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee (AGO OC) and the AGO Ovarian Cancer Study Group (AGO-OVAR)
Ann Surg Oncol 2006 online first 10-2006
Other publications
Advanced epithelial ovarian cancer: 1998 consensus statement
J.S. Berek, K. Bertelsen, A. du Bois, M.F. Brady, J. Carmichel, E.A. Eisenhauer, M. Gore, S. Grenman, T.C. Hamilton, S. W. Hansen, P.G. Harper, G. Horvath, S.B. Kaye, H.J. Lück, B. Lund, W.P. McGuire, J.P. Neijt, R.F. Ozols, M.K.B. Parmar, M.J. Piccart-Gebhart, R. van Rijswijk, P. Rosenberg, G.J.S. Rustin, C. Sessa, J.T. Thigpen, C. Tropé, M.K. Tuxen, I. Vergote, J.B. Vermorken, & P.H.B. Willemse
Ann Oncol 10 (suppl. 1): S87-S92 (1999)
J.S. Berek, K. Bertelsen, A. du Bois, M.F. Brady, J. Carmichel, E.A. Eisenhauer, M. Gore, S. Grenman, T.C. Hamilton, S. W. Hansen, P.G. Harper, G. Horvath, S.B. Kaye, H.J. Lück, B. Lund, W.P. McGuire, J.P. Neijt, R.F. Ozols, M.K.B. Parmar, M.J. Piccart-Gebhart, R. van Rijswijk, P. Rosenberg, G.J.S. Rustin, C. Sessa, J.T. Thigpen, C. Tropé, M.K. Tuxen, I. Vergote, J.B. Vermorken, & P.H.B. Willemse
Ann Oncol 10 (suppl. 1): S87-S92 (1999)
Ist eine effiziente klinische Forschung in der gynäkologischen Onkologie in Deutschland möglich? Historie und aktueller Stand am Beispiel der AGO-Ovarialkarzinom-Studien. Eine Stellungnahme der AGO Studiengruppe Ovarialkarzinom
du Bois A, Studiengruppe Ovarialkarzinom der Arbeitsgemeinschaft gynäkologische Onkologie (AGO)
Forum DKG 14: 815-824 (1999)
du Bois A, Studiengruppe Ovarialkarzinom der Arbeitsgemeinschaft gynäkologische Onkologie (AGO)
Forum DKG 14: 815-824 (1999)
Incidence of Venous Thromboembolism in Patients With Ovarian Cancer Undergoing Platinum/Paclitaxel-Containing First-Line Chemotherapie: An Exploratory Analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group
Christina Fotopoulou, Andreas du Bois, Alexandros N. Karavas, Ralf Trappe, Behnaz Aminossadati, Barbara Schmalfeldt, Jacobus Pfisterer and Jalid Sehouli
J Clin Oncol 26 (16): 2683-2689
Christina Fotopoulou, Andreas du Bois, Alexandros N. Karavas, Ralf Trappe, Behnaz Aminossadati, Barbara Schmalfeldt, Jacobus Pfisterer and Jalid Sehouli
J Clin Oncol 26 (16): 2683-2689
Welchen Einfluss haben Klinikmerkmale auf die Prognose beim Ovarialkarzinom in Deutschland? Analyse des Zusammenhangs zwischen Klinikmerkmalen auf Therapiequalität und Ergebnisse beim Ovarialkarzinom in Deutschland.
A. du Bois, J. Rochon, C. Lamparter, J. Pfisterer für die AGO Organkommission OVAR
Zentralbl Gynakol 2005; 127: 18–30 · © J. A. Barth Verlag in Georg Thieme Verlag KG DOI 10.1055/s-2005-836290 ISSN 0044-4197
A. du Bois, J. Rochon, C. Lamparter, J. Pfisterer für die AGO Organkommission OVAR
Zentralbl Gynakol 2005; 127: 18–30 · © J. A. Barth Verlag in Georg Thieme Verlag KG DOI 10.1055/s-2005-836290 ISSN 0044-4197
Die Therapie des fortgeschrittenen Ovarialkarzinoms in Deutschland: Welchen Einfluss hat die Teilnahme an klinischen Studien? Ergebnisse einer Umfrage der ORGANKOMMISSION OVAR der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) in der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) und der Deutschen Krebsgesellschaft (DKG)
A. du Bois, J. Pfisterer, Lenka Kellermann, R. Kreienberg
Geburtsh Frauenheilk 2001; 61: 863-871 © Thieme Verlag Stuttgart - New York - ISSN 0016-5751
A. du Bois, J. Pfisterer, Lenka Kellermann, R. Kreienberg
Geburtsh Frauenheilk 2001; 61: 863-871 © Thieme Verlag Stuttgart - New York - ISSN 0016-5751
QS-OVAR 2001
Das Qualitätssicherungsprogramm der AGO Organkommission OVAR (QS-OVAR): Versorgungsstruktur und Realität in Deutschland 2001
Analyse der Versorgungsstruktur und Qualität der Therapie des Ovarialkarzinoms in Deutschland. Untersuchung inwieweit die Therapieleitlinien umgesetzt werden, sowie Beschreibung von Prognosefaktoren.
A. du Bois, J. Rochon, C. Lamparter, J. Pfisterer
Zentralbl Gynakol 2005; 127: 9–17 · © J. A. Barth Verlag in Georg Thieme Verlag KG DOI 10.1055/s-2005-836289 ISSN 0044-4197
Das Qualitätssicherungsprogramm der AGO Organkommission OVAR (QS-OVAR): Versorgungsstruktur und Realität in Deutschland 2001
Analyse der Versorgungsstruktur und Qualität der Therapie des Ovarialkarzinoms in Deutschland. Untersuchung inwieweit die Therapieleitlinien umgesetzt werden, sowie Beschreibung von Prognosefaktoren.
A. du Bois, J. Rochon, C. Lamparter, J. Pfisterer
Zentralbl Gynakol 2005; 127: 9–17 · © J. A. Barth Verlag in Georg Thieme Verlag KG DOI 10.1055/s-2005-836289 ISSN 0044-4197
AGO-OVAR 3/QoL
Randomized Study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group Comparing Quality of Life in Patients With Ovarian Cancer Treated With Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel
Elfriede R. Greimel, Vesna Bjelic-Radisic, Jacobus Pfisterer, Felix Hilpert, Fedor Daghofer and Andreas du Bois
J Clin Oncol 24 (4): 579-586
Randomized Study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group Comparing Quality of Life in Patients With Ovarian Cancer Treated With Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel
Elfriede R. Greimel, Vesna Bjelic-Radisic, Jacobus Pfisterer, Felix Hilpert, Fedor Daghofer and Andreas du Bois
J Clin Oncol 24 (4): 579-586
AGO-OVAR 3 / Her-2/neu
Prognostic Value of Human Epidermal Growth Factor Receptor 2 (Her-2)/neu in Patients With Advanced Ovarian Cancer Treated With Platinum/Paclitaxel as First Line Chemotherapy. A Retrospective Evaluation of the AGO-OVAR 3 Trial by the AGO-OVAR Germany
Pfisterer J, du Bois A, Bentz EK, Kommoss F, Harter P, Huober J, Schmalfeldt B, Burchardi N, Arnold N, Hilpert F
Int J Gynecol Cancer 2009; 19:109-115
AGO-OVAR 14
Non-enrollment of ovarian cancer patients in clinical trials: Reasons and Backgrounds
Harter P, du Bois A, Schade-Brittinger C, Burges A, Wollschlaeger K, Gropp M, Schmalfeldt B, Huober J, Staehle A, Pfisterer J for the Study Coordination Group of the AGO-OVAR
Ann Oncol 16: 1801-1805, 2005
Non-enrollment of ovarian cancer patients in clinical trials: Reasons and Backgrounds
Harter P, du Bois A, Schade-Brittinger C, Burges A, Wollschlaeger K, Gropp M, Schmalfeldt B, Huober J, Staehle A, Pfisterer J for the Study Coordination Group of the AGO-OVAR
Ann Oncol 16: 1801-1805, 2005
Neurotox
Neuroprotection with amifostine in the 1st-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy - a double-blind, placebo-controlled, randomized phase II-study from the AGO Ovarian Cancer Study Group
Hilpert F, Stähle A, Tomé O, Burges A, Rossner D, Späthe K, Heilmann V, Richter B and du Bois A for the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) ovarian cancer study group
Support Care Cancer 2005 Oct; 13(10): 797-805
Neuroprotection with amifostine in the 1st-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy - a double-blind, placebo-controlled, randomized phase II-study from the AGO Ovarian Cancer Study Group
Hilpert F, Stähle A, Tomé O, Burges A, Rossner D, Späthe K, Heilmann V, Richter B and du Bois A for the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) ovarian cancer study group
Support Care Cancer 2005 Oct; 13(10): 797-805